Sign inCreate account

Report workspace tools

NCT02371603COMPLETEDanonymous

An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

GSK1278863

Indication / condition

AI-normalized

Anaemia

Intervention

Source record

GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet

Source & freshness

Source record

NCT ID

NCT02371603

Original source

ClinicalTrials.gov

Source last updated

Nov 17, 2017

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02371603

Title

An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

PHASE1

Condition raw

Anaemia

Condition normalized

Anaemia

Modality raw

Anaemia

Modality normalized

small molecule

Target raw

GSK1278863

Target normalized

GSK1278863

Interventions

GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet

Public preview

Source record

This clinical trial, sponsored by GlaxoSmithKline, evaluated the drug-drug interaction potential of GSK1278863 with pioglitazone and rosuvastatin in healthy volunteers. The study was designed to assess pharmacokinetics and safety profiles of GSK1278863 when co-administered with these drugs, which are known substrates of CYP2C8 and OATP1B1.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02371603

Status

COMPLETED

Phase

PHASE1

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by GlaxoSmithKline, evaluated the drug-drug interaction potential of GSK1278863 with pioglitazone and rosuvastatin in healthy volunteers. The study was designed to assess pharmacokinetics and safety profiles of GSK1278863 when co-administered with these drugs, which are known substrates of CYP2C8 and OATP1B1.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 17, 2017
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02371603

Indication

Anaemia

Modality

small molecule

Target

GSK1278863

Intervention

GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.